Capecitabine and Vinorelbine as First-Line Treatment in Elderly Patients (≥65 Years) with Metastatic Breast Cancer

Abstract

These regimens of capecitabine and vinorelbine are active and well tolerated in patients with advanced breast cancer > or =65 years. Response rates were comparable to published results. The lower capecitabine doses appeared appropriate given the advanced age, bone involvement and prior radiotherapy.